Lv42
778 积分 2024-11-01 加入
Targeting the SHOC2–RAS interaction in RAS-mutant cancers
9天前
已完结
Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor
18天前
已关闭
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
1个月前
已完结
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC
1个月前
已完结
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
3个月前
已完结
Novel Macrocyclic NLRP3 Inhibitors
6个月前
已完结
Pharmacologic restoration of GTP hydrolysis by mutant RAS
8个月前
已完结
皖公网安备34019202002308
